Global Neuroprotection

Neuroprotection Comprehensive Study by Type (Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs), Metal Ion Chelators, Stimulants, Others), Application (Prevention, Treatment), Disease Type (Alzheimer's disease, Multiple sclerosis, Parkinson's disease, Ocular degeneration (retinal disorders), Amyotrophic lateral sclerosis (ALS), Huntington's disease, Neuropathies, Brain injury, Other) Players and Region - Global Market Outlook to 2026

Neuroprotection Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Neuroprotection Market?

Neuroprotection refers to a disease-modifying event that aims to protect the nervous system from injury and damage, especially in people who sustain an injury or develop a health condition that has neurological effects. The factors such as increased incidences of CNS disorders and increasing demand for more target-specific drug treatment for neurodegenerative diseases are driving the global neuroprotection market.

The market study is being classified by Type (Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs), Metal Ion Chelators, Stimulants and Others), by Application (Prevention and Treatment) and major geographies with country level break-up.

Daiichi Sankyo Company (Japan), Eli Lilly and Company (United States), Allergan, Inc. (Ireland), Dr. Reddy’s Laboratories (India), Teva Pharmaceutical (Israel), Novartis International AG (Switzerland), AstraZeneca plc (United Kingdom), Astrocyte Pharmaceuticals (United States), Roche Holding AG (Switzerland) and Biogen Inc. (United States) are some of the key players profiled in the study.

There are various companies that are operating in the new geographical regions by adopting various market growth initiatives such as mergers & acquisitions, expansions, investments, and others. There are various new market players are entering the market to capture market growth opportunities. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Neuroprotection market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Neuroprotection market by Type, Application and Region.

On the basis of geography, the market of Neuroprotection has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Neurological Disorders
  • Limitations of Current Pharmacological Treatments for Neurogenerative Diseases

Market Trend
  • Advancements in the Medical Science

Restraints
  • High Cost of Research and Development Investment


Challenges
  • Stringent Government Rules and Regulations





Key Target Audience
Neuroprotection Products Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users

Report Objectives / Segmentation Covered

By Type
  • Free Radical Trapping Agents (Antioxidants)
  • Glutamate Antagonists (Anti-Excitotoxic Agents)
  • Apoptosis Inhibitors
  • Anti-inflammatory Agents
  • Neurotrophic Factors (NTFs)
  • Metal Ion Chelators
  • Stimulants
  • Others
By Application
  • Prevention
  • Treatment
By Disease Type
  • Alzheimer's disease
  • Multiple sclerosis
  • Parkinson's disease
  • Ocular degeneration (retinal disorders)
  • Amyotrophic lateral sclerosis (ALS)
  • Huntington's disease
  • Neuropathies
  • Brain injury
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Neurological Disorders
      • 3.2.2. Limitations of Current Pharmacological Treatments for Neurogenerative Diseases
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Advancements in the Medical Science
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neuroprotection, by Type, Application, Disease Type and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Neuroprotection (Value)
      • 5.2.1. Global Neuroprotection by: Type (Value)
        • 5.2.1.1. Free Radical Trapping Agents (Antioxidants)
        • 5.2.1.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
        • 5.2.1.3. Apoptosis Inhibitors
        • 5.2.1.4. Anti-inflammatory Agents
        • 5.2.1.5. Neurotrophic Factors (NTFs)
        • 5.2.1.6. Metal Ion Chelators
        • 5.2.1.7. Stimulants
        • 5.2.1.8. Others
      • 5.2.2. Global Neuroprotection by: Application (Value)
        • 5.2.2.1. Prevention
        • 5.2.2.2. Treatment
      • 5.2.3. Global Neuroprotection by: Disease Type (Value)
        • 5.2.3.1. Alzheimer's disease
        • 5.2.3.2. Multiple sclerosis
        • 5.2.3.3. Parkinson's disease
        • 5.2.3.4. Ocular degeneration (retinal disorders)
        • 5.2.3.5. Amyotrophic lateral sclerosis (ALS)
        • 5.2.3.6. Huntington's disease
        • 5.2.3.7. Neuropathies
        • 5.2.3.8. Brain injury
        • 5.2.3.9. Other
      • 5.2.4. Global Neuroprotection Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Neuroprotection: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Daiichi Sankyo Company (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Allergan, Inc. (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Dr. Reddy’s Laboratories (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceutical (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis International AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AstraZeneca plc (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Astrocyte Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Roche Holding AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Biogen Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Neuroprotection Sale, by Type, Application, Disease Type and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Neuroprotection (Value)
      • 7.2.1. Global Neuroprotection by: Type (Value)
        • 7.2.1.1. Free Radical Trapping Agents (Antioxidants)
        • 7.2.1.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
        • 7.2.1.3. Apoptosis Inhibitors
        • 7.2.1.4. Anti-inflammatory Agents
        • 7.2.1.5. Neurotrophic Factors (NTFs)
        • 7.2.1.6. Metal Ion Chelators
        • 7.2.1.7. Stimulants
        • 7.2.1.8. Others
      • 7.2.2. Global Neuroprotection by: Application (Value)
        • 7.2.2.1. Prevention
        • 7.2.2.2. Treatment
      • 7.2.3. Global Neuroprotection by: Disease Type (Value)
        • 7.2.3.1. Alzheimer's disease
        • 7.2.3.2. Multiple sclerosis
        • 7.2.3.3. Parkinson's disease
        • 7.2.3.4. Ocular degeneration (retinal disorders)
        • 7.2.3.5. Amyotrophic lateral sclerosis (ALS)
        • 7.2.3.6. Huntington's disease
        • 7.2.3.7. Neuropathies
        • 7.2.3.8. Brain injury
        • 7.2.3.9. Other
      • 7.2.4. Global Neuroprotection Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neuroprotection: by Type(USD Million)
  • Table 2. Neuroprotection Free Radical Trapping Agents (Antioxidants) , by Region USD Million (2015-2020)
  • Table 3. Neuroprotection Glutamate Antagonists (Anti-Excitotoxic Agents) , by Region USD Million (2015-2020)
  • Table 4. Neuroprotection Apoptosis Inhibitors , by Region USD Million (2015-2020)
  • Table 5. Neuroprotection Anti-inflammatory Agents , by Region USD Million (2015-2020)
  • Table 6. Neuroprotection Neurotrophic Factors (NTFs) , by Region USD Million (2015-2020)
  • Table 7. Neuroprotection Metal Ion Chelators , by Region USD Million (2015-2020)
  • Table 8. Neuroprotection Stimulants , by Region USD Million (2015-2020)
  • Table 9. Neuroprotection Others , by Region USD Million (2015-2020)
  • Table 10. Neuroprotection: by Application(USD Million)
  • Table 11. Neuroprotection Prevention , by Region USD Million (2015-2020)
  • Table 12. Neuroprotection Treatment , by Region USD Million (2015-2020)
  • Table 13. Neuroprotection: by Disease Type(USD Million)
  • Table 14. Neuroprotection Alzheimer's disease , by Region USD Million (2015-2020)
  • Table 15. Neuroprotection Multiple sclerosis , by Region USD Million (2015-2020)
  • Table 16. Neuroprotection Parkinson's disease , by Region USD Million (2015-2020)
  • Table 17. Neuroprotection Ocular degeneration (retinal disorders) , by Region USD Million (2015-2020)
  • Table 18. Neuroprotection Amyotrophic lateral sclerosis (ALS) , by Region USD Million (2015-2020)
  • Table 19. Neuroprotection Huntington's disease , by Region USD Million (2015-2020)
  • Table 20. Neuroprotection Neuropathies , by Region USD Million (2015-2020)
  • Table 21. Neuroprotection Brain injury , by Region USD Million (2015-2020)
  • Table 22. Neuroprotection Other , by Region USD Million (2015-2020)
  • Table 23. South America Neuroprotection, by Country USD Million (2015-2020)
  • Table 24. South America Neuroprotection, by Type USD Million (2015-2020)
  • Table 25. South America Neuroprotection, by Application USD Million (2015-2020)
  • Table 26. South America Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 27. Brazil Neuroprotection, by Type USD Million (2015-2020)
  • Table 28. Brazil Neuroprotection, by Application USD Million (2015-2020)
  • Table 29. Brazil Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 30. Argentina Neuroprotection, by Type USD Million (2015-2020)
  • Table 31. Argentina Neuroprotection, by Application USD Million (2015-2020)
  • Table 32. Argentina Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 33. Rest of South America Neuroprotection, by Type USD Million (2015-2020)
  • Table 34. Rest of South America Neuroprotection, by Application USD Million (2015-2020)
  • Table 35. Rest of South America Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 36. Asia Pacific Neuroprotection, by Country USD Million (2015-2020)
  • Table 37. Asia Pacific Neuroprotection, by Type USD Million (2015-2020)
  • Table 38. Asia Pacific Neuroprotection, by Application USD Million (2015-2020)
  • Table 39. Asia Pacific Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 40. China Neuroprotection, by Type USD Million (2015-2020)
  • Table 41. China Neuroprotection, by Application USD Million (2015-2020)
  • Table 42. China Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 43. Japan Neuroprotection, by Type USD Million (2015-2020)
  • Table 44. Japan Neuroprotection, by Application USD Million (2015-2020)
  • Table 45. Japan Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 46. India Neuroprotection, by Type USD Million (2015-2020)
  • Table 47. India Neuroprotection, by Application USD Million (2015-2020)
  • Table 48. India Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 49. South Korea Neuroprotection, by Type USD Million (2015-2020)
  • Table 50. South Korea Neuroprotection, by Application USD Million (2015-2020)
  • Table 51. South Korea Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 52. Taiwan Neuroprotection, by Type USD Million (2015-2020)
  • Table 53. Taiwan Neuroprotection, by Application USD Million (2015-2020)
  • Table 54. Taiwan Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 55. Australia Neuroprotection, by Type USD Million (2015-2020)
  • Table 56. Australia Neuroprotection, by Application USD Million (2015-2020)
  • Table 57. Australia Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 58. Rest of Asia-Pacific Neuroprotection, by Type USD Million (2015-2020)
  • Table 59. Rest of Asia-Pacific Neuroprotection, by Application USD Million (2015-2020)
  • Table 60. Rest of Asia-Pacific Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 61. Europe Neuroprotection, by Country USD Million (2015-2020)
  • Table 62. Europe Neuroprotection, by Type USD Million (2015-2020)
  • Table 63. Europe Neuroprotection, by Application USD Million (2015-2020)
  • Table 64. Europe Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 65. Germany Neuroprotection, by Type USD Million (2015-2020)
  • Table 66. Germany Neuroprotection, by Application USD Million (2015-2020)
  • Table 67. Germany Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 68. France Neuroprotection, by Type USD Million (2015-2020)
  • Table 69. France Neuroprotection, by Application USD Million (2015-2020)
  • Table 70. France Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 71. Italy Neuroprotection, by Type USD Million (2015-2020)
  • Table 72. Italy Neuroprotection, by Application USD Million (2015-2020)
  • Table 73. Italy Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 74. United Kingdom Neuroprotection, by Type USD Million (2015-2020)
  • Table 75. United Kingdom Neuroprotection, by Application USD Million (2015-2020)
  • Table 76. United Kingdom Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 77. Netherlands Neuroprotection, by Type USD Million (2015-2020)
  • Table 78. Netherlands Neuroprotection, by Application USD Million (2015-2020)
  • Table 79. Netherlands Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 80. Rest of Europe Neuroprotection, by Type USD Million (2015-2020)
  • Table 81. Rest of Europe Neuroprotection, by Application USD Million (2015-2020)
  • Table 82. Rest of Europe Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 83. MEA Neuroprotection, by Country USD Million (2015-2020)
  • Table 84. MEA Neuroprotection, by Type USD Million (2015-2020)
  • Table 85. MEA Neuroprotection, by Application USD Million (2015-2020)
  • Table 86. MEA Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 87. Middle East Neuroprotection, by Type USD Million (2015-2020)
  • Table 88. Middle East Neuroprotection, by Application USD Million (2015-2020)
  • Table 89. Middle East Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 90. Africa Neuroprotection, by Type USD Million (2015-2020)
  • Table 91. Africa Neuroprotection, by Application USD Million (2015-2020)
  • Table 92. Africa Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 93. North America Neuroprotection, by Country USD Million (2015-2020)
  • Table 94. North America Neuroprotection, by Type USD Million (2015-2020)
  • Table 95. North America Neuroprotection, by Application USD Million (2015-2020)
  • Table 96. North America Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 97. United States Neuroprotection, by Type USD Million (2015-2020)
  • Table 98. United States Neuroprotection, by Application USD Million (2015-2020)
  • Table 99. United States Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 100. Canada Neuroprotection, by Type USD Million (2015-2020)
  • Table 101. Canada Neuroprotection, by Application USD Million (2015-2020)
  • Table 102. Canada Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 103. Mexico Neuroprotection, by Type USD Million (2015-2020)
  • Table 104. Mexico Neuroprotection, by Application USD Million (2015-2020)
  • Table 105. Mexico Neuroprotection, by Disease Type USD Million (2015-2020)
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Neuroprotection: by Type(USD Million)
  • Table 117. Neuroprotection Free Radical Trapping Agents (Antioxidants) , by Region USD Million (2021-2026)
  • Table 118. Neuroprotection Glutamate Antagonists (Anti-Excitotoxic Agents) , by Region USD Million (2021-2026)
  • Table 119. Neuroprotection Apoptosis Inhibitors , by Region USD Million (2021-2026)
  • Table 120. Neuroprotection Anti-inflammatory Agents , by Region USD Million (2021-2026)
  • Table 121. Neuroprotection Neurotrophic Factors (NTFs) , by Region USD Million (2021-2026)
  • Table 122. Neuroprotection Metal Ion Chelators , by Region USD Million (2021-2026)
  • Table 123. Neuroprotection Stimulants , by Region USD Million (2021-2026)
  • Table 124. Neuroprotection Others , by Region USD Million (2021-2026)
  • Table 125. Neuroprotection: by Application(USD Million)
  • Table 126. Neuroprotection Prevention , by Region USD Million (2021-2026)
  • Table 127. Neuroprotection Treatment , by Region USD Million (2021-2026)
  • Table 128. Neuroprotection: by Disease Type(USD Million)
  • Table 129. Neuroprotection Alzheimer's disease , by Region USD Million (2021-2026)
  • Table 130. Neuroprotection Multiple sclerosis , by Region USD Million (2021-2026)
  • Table 131. Neuroprotection Parkinson's disease , by Region USD Million (2021-2026)
  • Table 132. Neuroprotection Ocular degeneration (retinal disorders) , by Region USD Million (2021-2026)
  • Table 133. Neuroprotection Amyotrophic lateral sclerosis (ALS) , by Region USD Million (2021-2026)
  • Table 134. Neuroprotection Huntington's disease , by Region USD Million (2021-2026)
  • Table 135. Neuroprotection Neuropathies , by Region USD Million (2021-2026)
  • Table 136. Neuroprotection Brain injury , by Region USD Million (2021-2026)
  • Table 137. Neuroprotection Other , by Region USD Million (2021-2026)
  • Table 138. South America Neuroprotection, by Country USD Million (2021-2026)
  • Table 139. South America Neuroprotection, by Type USD Million (2021-2026)
  • Table 140. South America Neuroprotection, by Application USD Million (2021-2026)
  • Table 141. South America Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 142. Brazil Neuroprotection, by Type USD Million (2021-2026)
  • Table 143. Brazil Neuroprotection, by Application USD Million (2021-2026)
  • Table 144. Brazil Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 145. Argentina Neuroprotection, by Type USD Million (2021-2026)
  • Table 146. Argentina Neuroprotection, by Application USD Million (2021-2026)
  • Table 147. Argentina Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 148. Rest of South America Neuroprotection, by Type USD Million (2021-2026)
  • Table 149. Rest of South America Neuroprotection, by Application USD Million (2021-2026)
  • Table 150. Rest of South America Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 151. Asia Pacific Neuroprotection, by Country USD Million (2021-2026)
  • Table 152. Asia Pacific Neuroprotection, by Type USD Million (2021-2026)
  • Table 153. Asia Pacific Neuroprotection, by Application USD Million (2021-2026)
  • Table 154. Asia Pacific Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 155. China Neuroprotection, by Type USD Million (2021-2026)
  • Table 156. China Neuroprotection, by Application USD Million (2021-2026)
  • Table 157. China Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 158. Japan Neuroprotection, by Type USD Million (2021-2026)
  • Table 159. Japan Neuroprotection, by Application USD Million (2021-2026)
  • Table 160. Japan Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 161. India Neuroprotection, by Type USD Million (2021-2026)
  • Table 162. India Neuroprotection, by Application USD Million (2021-2026)
  • Table 163. India Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 164. South Korea Neuroprotection, by Type USD Million (2021-2026)
  • Table 165. South Korea Neuroprotection, by Application USD Million (2021-2026)
  • Table 166. South Korea Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 167. Taiwan Neuroprotection, by Type USD Million (2021-2026)
  • Table 168. Taiwan Neuroprotection, by Application USD Million (2021-2026)
  • Table 169. Taiwan Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 170. Australia Neuroprotection, by Type USD Million (2021-2026)
  • Table 171. Australia Neuroprotection, by Application USD Million (2021-2026)
  • Table 172. Australia Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 173. Rest of Asia-Pacific Neuroprotection, by Type USD Million (2021-2026)
  • Table 174. Rest of Asia-Pacific Neuroprotection, by Application USD Million (2021-2026)
  • Table 175. Rest of Asia-Pacific Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 176. Europe Neuroprotection, by Country USD Million (2021-2026)
  • Table 177. Europe Neuroprotection, by Type USD Million (2021-2026)
  • Table 178. Europe Neuroprotection, by Application USD Million (2021-2026)
  • Table 179. Europe Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 180. Germany Neuroprotection, by Type USD Million (2021-2026)
  • Table 181. Germany Neuroprotection, by Application USD Million (2021-2026)
  • Table 182. Germany Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 183. France Neuroprotection, by Type USD Million (2021-2026)
  • Table 184. France Neuroprotection, by Application USD Million (2021-2026)
  • Table 185. France Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 186. Italy Neuroprotection, by Type USD Million (2021-2026)
  • Table 187. Italy Neuroprotection, by Application USD Million (2021-2026)
  • Table 188. Italy Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 189. United Kingdom Neuroprotection, by Type USD Million (2021-2026)
  • Table 190. United Kingdom Neuroprotection, by Application USD Million (2021-2026)
  • Table 191. United Kingdom Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 192. Netherlands Neuroprotection, by Type USD Million (2021-2026)
  • Table 193. Netherlands Neuroprotection, by Application USD Million (2021-2026)
  • Table 194. Netherlands Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 195. Rest of Europe Neuroprotection, by Type USD Million (2021-2026)
  • Table 196. Rest of Europe Neuroprotection, by Application USD Million (2021-2026)
  • Table 197. Rest of Europe Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 198. MEA Neuroprotection, by Country USD Million (2021-2026)
  • Table 199. MEA Neuroprotection, by Type USD Million (2021-2026)
  • Table 200. MEA Neuroprotection, by Application USD Million (2021-2026)
  • Table 201. MEA Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 202. Middle East Neuroprotection, by Type USD Million (2021-2026)
  • Table 203. Middle East Neuroprotection, by Application USD Million (2021-2026)
  • Table 204. Middle East Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 205. Africa Neuroprotection, by Type USD Million (2021-2026)
  • Table 206. Africa Neuroprotection, by Application USD Million (2021-2026)
  • Table 207. Africa Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 208. North America Neuroprotection, by Country USD Million (2021-2026)
  • Table 209. North America Neuroprotection, by Type USD Million (2021-2026)
  • Table 210. North America Neuroprotection, by Application USD Million (2021-2026)
  • Table 211. North America Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 212. United States Neuroprotection, by Type USD Million (2021-2026)
  • Table 213. United States Neuroprotection, by Application USD Million (2021-2026)
  • Table 214. United States Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 215. Canada Neuroprotection, by Type USD Million (2021-2026)
  • Table 216. Canada Neuroprotection, by Application USD Million (2021-2026)
  • Table 217. Canada Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 218. Mexico Neuroprotection, by Type USD Million (2021-2026)
  • Table 219. Mexico Neuroprotection, by Application USD Million (2021-2026)
  • Table 220. Mexico Neuroprotection, by Disease Type USD Million (2021-2026)
  • Table 221. Research Programs/Design for This Report
  • Table 222. Key Data Information from Secondary Sources
  • Table 223. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neuroprotection: by Type USD Million (2015-2020)
  • Figure 5. Global Neuroprotection: by Application USD Million (2015-2020)
  • Figure 6. Global Neuroprotection: by Disease Type USD Million (2015-2020)
  • Figure 7. South America Neuroprotection Share (%), by Country
  • Figure 8. Asia Pacific Neuroprotection Share (%), by Country
  • Figure 9. Europe Neuroprotection Share (%), by Country
  • Figure 10. MEA Neuroprotection Share (%), by Country
  • Figure 11. North America Neuroprotection Share (%), by Country
  • Figure 12. Global Neuroprotection share by Players 2020 (%)
  • Figure 13. Global Neuroprotection share by Players (Top 3) 2020(%)
  • Figure 14. Global Neuroprotection share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Daiichi Sankyo Company (Japan) Revenue, Net Income and Gross profit
  • Figure 17. Daiichi Sankyo Company (Japan) Revenue: by Geography 2020
  • Figure 18. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 19. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 20. Allergan, Inc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 21. Allergan, Inc. (Ireland) Revenue: by Geography 2020
  • Figure 22. Dr. Reddy’s Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 23. Dr. Reddy’s Laboratories (India) Revenue: by Geography 2020
  • Figure 24. Teva Pharmaceutical (Israel) Revenue, Net Income and Gross profit
  • Figure 25. Teva Pharmaceutical (Israel) Revenue: by Geography 2020
  • Figure 26. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 28. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 30. Astrocyte Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 31. Astrocyte Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 32. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Roche Holding AG (Switzerland) Revenue: by Geography 2020
  • Figure 34. Biogen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Biogen Inc. (United States) Revenue: by Geography 2020
  • Figure 36. Global Neuroprotection: by Type USD Million (2021-2026)
  • Figure 37. Global Neuroprotection: by Application USD Million (2021-2026)
  • Figure 38. Global Neuroprotection: by Disease Type USD Million (2021-2026)
  • Figure 39. South America Neuroprotection Share (%), by Country
  • Figure 40. Asia Pacific Neuroprotection Share (%), by Country
  • Figure 41. Europe Neuroprotection Share (%), by Country
  • Figure 42. MEA Neuroprotection Share (%), by Country
  • Figure 43. North America Neuroprotection Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Daiichi Sankyo Company (Japan)
  • Eli Lilly and Company (United States)
  • Allergan, Inc. (Ireland)
  • Dr. Reddy’s Laboratories (India)
  • Teva Pharmaceutical (Israel)
  • Novartis International AG (Switzerland)
  • AstraZeneca plc (United Kingdom)
  • Astrocyte Pharmaceuticals (United States)
  • Roche Holding AG (Switzerland)
  • Biogen Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2021 227 Pages 93 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Neuroprotection Quantitative research analysis
Global Neuroprotection Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Neurological Disorders " is seen as one of major growth factors of Neuroprotection Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Neuroprotection Report?

Have a Query? Click Here

Other Related Reports

Human Rabies Immunoglobulin Comprehensive Study by Side effects (Pain, Fever, Headache, Others), Rabies (Encephalitic, Paralytic), Immunoglobulin (IgG, IgM, IgA, IgD, IgE) Players and Region - Globa...
$ 3500
Flu Vaccine Comprehensive Study by Type (Whole Virus Vaccines, Split Virus Vaccines, Subunit Vaccines, Live Attenuated Virus Vaccines), Application (For Children (6 months to 3 years), For Adults and...
$ 3450
Vascular Graft Comprehensive Study by Raw Material (Polyester, EPTFE, Polyurethane, Biosyntheti), Indication (EVAR (Abdominal Aneurysm Repair & Thoracic Aneurysm0, Peripheral Vascular Repair, Hemodia...
$ 3450
Hirudin Comprehensive Study by Type (Natural Hirudin, Recombinant Hirudin), Disease Indication (Heparin-Induced Thrombocytopenia, Unstable Angina, Tumors, Others) Players and Region - Global Market O...
$ 3500
Prednisolone Acetate Comprehensive Study by Type (Prednisolone Acetate Tablet, Prednisolone Acetate Liquid, Prednisolone Acetate Emulsifiable Paste), Application (Hypersensitivity Disease, Autoimmune...
$ 3450
Sacral Nerve Stimulation Comprehensive Study by Type (Implantable, External), Application (Urinary & Fecal Incontinence, Urge Incontinence, Chronic Anal Fissure, Others), End User (Hospitals, Ambulat...
$ 3350